Search Results - "Leiter, L.A."

Effect of canagliflozin on liver function tests in patients with type 2 diabetes by Leiter, L.A, Forst, T, Polidori, D, Balis, D.A, Xie, J, Sha, S

“…Abstract Aims To report changes in liver function tests observed with canagliflozin, a sodium glucose co-transporter 2 inhibitor, across phase 3 studies in…”
Get full text

The effect of a dietary portfolio compared to a DASH-type diet on blood pressure by Jenkins, D.J.A, Jones, P.J, Frohlich, J, Lamarche, B, Ireland, C, Nishi, S.K, Srichaikul, K, Galange, P, Pellini, C, Faulkner, D, de Souza, R.J, Sievenpiper, J.L, Mirrahimi, A, Jayalath, V.H, Augustin, L.S, Bashyam, B, Leiter, L.A, Josse, R, Couture, P, Ramprasath, V, Kendall, C.W.C

“…Abstract Background and aim Compared to a DASH-type diet, an intensively applied dietary portfolio reduced diastolic blood pressure at 24 weeks as a secondary…”
Get full text

Viscosity of fiber preloads affects food intake in adolescents by Vuksan, V, Panahi, S, Lyon, M, Rogovik, A.L, Jenkins, A.L, Leiter, L.A

“…Abstract Background and aims Dietary fiber that develops viscosity in the gastrointestinal tract is capable of addressing various aspects of food intake…”
Get full text

Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM–INSULIN trial by Cariou, B, Leiter, L.A, Müller-Wieland, D, Bigot, G, Colhoun, H.M, Del Prato, S, Henry, R.R, Tinahones, F.J, Letierce, A, Aurand, L, Maroni, J, Ray, K.K, Bujas-Bobanovic, M

“…Abstract Aims The coadministration of alirocumab, a PCSK9 inhibitor for treatment of hypercholesterolaemia, and insulin in diabetes mellitus (DM) requires…”
Get full text

ALIROCUMAB EFFICACY AND SAFETY IN PATIENTS WITH PRE-DIABETES VERSUS NORMOGLYCEMIA by Leiter, L.A, Müller-Wieland, D, Baccara-Dinet, M.T, Letierce, A, Samuel, R, Cariou, B

Get full text

Effects of canagliflozin versus glimepiride on adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes mellitus by Garvey, W.T., Gaal, L.V., Leiter, L.A., Vijapurkar, U., List, J., Cuddihy, R., Ren, J., Davies, M.J., Fegade, M.

Get full text

GLYCEMIC CONTROL AND CARDIOVASCULAR RISK FACTOR MANAGEMENT IN PATIENTS WITH DIABETES WITH AND WITHOUT CORONARY ARTERY DISEASE: INSIGHTS FROM THE DIABETES MELLITUS STATUS IN CANADA (DM-SCAN) SURVEY by Wang, J.Y, Leiter, L.A, Langer, A, Tan, M.K, Goldin, L, Teoh, H, Cheng, A.Y, Connelly, K.A, Goodman, S.G, Yan, A.T

Get full text

EXAGGERATED CARDIOMETABOLIC RISK FACTORS AND CARDIOVASCULAR DISEASE IN CANADIAN PRIMARY CARE PATIENTS WITH DIABETES AND ABDOMINAL OBESITY by Lau, D.C, Leiter, L.A, Genest, J, Harris, S.B, Selby, P, Taylor, V, Bujas-Bobanovic, M, Stewart, J

Get full text

A CROSS-SECTIONAL SURVEY OF CARDIOMETABOLIC RISK FACTORS IN PRIMARY CARE PATIENTS WITH ABDOMINAL OBESITY IN CANADA by Lau, D.C, Leiter, L.A, Genest, J, Harris, S.B, Selby, P, Taylor, V, Bujas-Bobanovic, M, Stewart, J

Get full text

BLOOD PRESSURE MANAGEMENT IN PATIENTS WITH DIABETES: INSIGHTS FROM THE DIABETES MELLITUS STATUS IN CANADA (DM-SCAN) SURVEY by Grenier, J, Goodman, S.G, Leiter, L.A, Langer, A, Connelly, K, Teoh, H, Bhatt, D.L, Cheng, A.Y, Tan, M.K, Ransom, T, Yan, A.T

Get full text

Altering source or amount of dietary carbohydrate has acute and chronic effects on postprandial glucose and triglycerides in type 2 diabetes: Canadian trial of Carbohydrates in Diabetes (CCD) by Wolever, T.M.S, Gibbs, A.L, Chiasson, J.-L, Connelly, P.W, Josse, R.G, Leiter, L.A, Maheux, P, Rabasa-Lhoret, R, Rodger, N.W, Ryan, E.A

“…Abstract Background and aims Nutrition recommendations for type 2 diabetes (T2DM) are partly guided by the postprandial responses elicited by diets varying in…”
Get full text

NUMBER OF TRADITIONAL CARDIOVASCULAR RISK FACTORS AND MANAGEMENT AND OUTCOME IN ACUTE CORONARY SYNDROME by Wang, J.Y, Goodman, S.G, Saltzman, I, Wong, G.C, Huynh, T, Dery, J.P, Leiter, L.A, Bhatt, D.L, Welsh, R.C, Spencer, F.A, Fox, K.A, Yan, A.T

Get full text

787 Snapshot of Glycemic Management in Patients Presenting With Acute Coronary Syndromes: Survey of Care by Cardiologists and Endocrinologists Across Canada by O'Neill, B.J, Gupta, M, Verma, S, Tsigoulis, M, Mann, U, Leiter, L.A

Get full text

Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: The Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study by Martineau, P, Gaw, A, de Teresa, E, Farsang, C, Gensini, G.F, Leiter, L.A, Langer, A

“…Abstract Aims To investigate whether selecting the starting dose of atorvastatin according to baseline and target (<2.6 mmol/L) LDL-cholesterol (LDL-C) values…”
Get full text

Effect of atorvastatin on circulating hsCRP concentrations: A sub-study of the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study by Gensini, G.F, Gori, A.M, Dilaghi, B, Rostagno, C, Gaw, A, Blanco-Colio, L.M, de Teresa, E, Egido, J, Farsang, C, Leiter, L.A, Martineau, P, Nozza, A, Langer, A

“…Abstract Background Elevated C-reactive protein (CRP) concentration is a risk factor for cardiovascular events that may add prognostic information. Statin…”
Get full text

750 Are Lifestyle Modifications Being Appropriately Recommended in the Canadian Primary Care Practice to Manage Elevated Cardiometabolic Risk? by Teoh, H, Després, J.P, Fitchett, D.H, Galluzzi, A, Goldin, L, Goodman, S.G, Harris, S.B, Langer, A, Lonn, E.M, Mancini, G.B.J, McFarlane, P.A, Poirier, P, Rabasa-Lhoret, R, Leiter, L.A

Get full text

248 Underestimation of Cardiovascular Risk in Patients With Elevated Cardiometabolic Risk in the Canadian Primary Care Setting by Teoh, H, Després, J.P, Fitchett, D.H, Galluzzi, A, Goldin, L, Goodman, S.G, Harris, S.B, Langer, A, Lonn, E.M, Mancini, G.B.J, McFarlane, P.A, Poirier, P, Rabasa-Lhoret, R, Leiter, L.A

Get full text

247 How Do Canadian Primary Care Physicians in Family Health Teams Compare With Those in Solo-Physician Practices in Their Assessment and Management of Patients With Elevated Cardiometabolic Risk? by Teoh, H, Després, J.P, Fitchett, D.H, Galluzzi, A, Goldin, L, Goodman, S.G, Harris, S.B, Langer, A, Lonn, E.M, Mancini, G.B.J, McFarlane, P.A, Poirier, P, Rabasa-Lhoret, R, Leiter, L.A

Get full text

Glycemic Management in Patients Presenting with Acute Coronary Syndromes: Survey of Care by Canadian Endocrinologists and Cardiologists by Leiter, L.A, Gupta, M, Verma, S, Tsigoulis, M, Mann, U, O'neill, B.J

Get full text

PCV55 Cost-Effectiveness of Icosapent Ethyl (IPE) for the Reduction of the Risk of Ischemic Cardiovascular Events in Canada by Lachaine, J., Charron, J.N., Gregoire, J.C., Hegele, R.A., Leiter, L.A.

Get full text